Document is current
Any future updates will be listed below
-
Authors
Rodríguez, Francisco J. http://orcid.org/0000-0002-1728-3444
Wu, Lihteh
Bordon, Arnaldo F.
Charles, Martin
Lee, JinKyung
Machewitz, Tobias
Mueller, Margarete
Gay, Gabriela del Carmen
Fromow-Guerra, Jans
,
Reinhart, Marcelo
Caride, Gastón Gómez
Negri, Herminio
Galván, Gerónimo
Irungaray, Juan
Irós, Mariano
Vidosevich, Matko
Rivero, Noe
Zompa, Tamara
Francos, Juan Pablo
Salgado, Paula
Caceres Barrios, Gerardo
Regnasco, Octavio
Rodríguez, Francisco J.
Piñeros, Hildegard
Arias, Juan
Buendia, Javier
Navarro Naranjo, Gustavo Adolfo
Endo, Beatriz
Hernandez, Myrian
Wu, Lihteh
Evans Tinoco, Teodoro
Garcia, Gerardo
Padilla, Andres
Gómez Cespedes, Adriana
Dalma, Jose
Cano, Rene
Fromow-Guerra, Jans
Saldaña, Natalia
Jimenez, Juan Manuel
García Franco, Renata del Carmen
Solis Vivanco, Adriana
Hernandez Vazquez, Angeles Yael
-
Funding
Funding for this research was provided by:
Bayer AG
- License Information
-
More Information
Article History
Received: 24 May 2022
Accepted: 3 July 2022
First Online: 2 August 2022
Declarations
:
: The AQUILA study was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation guideline E6: Good Clinical Practice. The protocol and any amendments were reviewed and approved by each study site’s Independent Ethics Committee or Institutional Review Board before the start of the study.
: Not applicable.
: Francisco J. Rodríguez: Consultant: Bayer, Novartis, and Roche; Speaker: Bayer, Novartis, and Roche; Research funds: Novartis; Lihteh Wu: Speaker: Bayer, and Quantel Medical; Arnaldo F. Bordon: Speaker: Allergan, Bayer, and Novartis; Martin Charles: Consultant: Alcon; Speaker: Alcon, Bayer, and Novartis; Research funds: Alcon; JinKyung Lee: Employee: Bayer AG, Berlin, Germany; Tobias Machewitz: Employee: Bayer AG, Berlin, Germany; Margarete Mueller: Employee: Bayer AG, Berlin, Germany; Gabriela del Carmen Gay: Employee: Bayer SA, Munro, Argentina; Jans Fromow-Guerra: Consultant: Bayer and Novartis; Speaker: Bayer, DORC, IOSA, and Novartis.
